Placebo-controlled, double-blind, exploratory study of NS-304 in lumbar spinal stenosis (LSS) patients with intermittent claudication (Early Phase II study)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223810

Enrollment

120

Registered

2018-02-15

Start date

2018-02-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

LSS

Interventions

investigational material(s) Generic name etc : NS-304 INN of investigational material : Selexipag Therapeutic category code : 219 Other cardiovascular agents Dosage and Administration for Investigatio

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: LSS patients with intermittent claudication

Exclusion criteria

Exclusion criteria: Patients with LSS-associated symptoms considered to be indicated for surgery

Design outcomes

Primary

Measure	Time frame
efficacy Change in walking distance from the baseline	—

Secondary

Measure	Time frame
efficacy Change in walking duration from the baseline	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026